{"nct_id":"NCT01911221","title":"A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.","status":"COMPLETED","status_verified_date":"2017-05","start_date":"2013-08","start_date_type":null,"primary_completion_date":"2014-04","primary_completion_date_type":"ACTUAL","completion_date":"2014-04","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["NVS"]}